Alpha Teknova (TKNO) 10-Q 13 May 24 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 10, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Entity Registrant Name	ALPHA TEKNOVA, INC.
Entity Central Index Key	0001850902
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Document Fiscal Period Focus	Q1
Trading Symbol	TKNO
Security12b Title	Common Stock, par value $0.00001 per share
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-40538
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3368109
Entity Address, Address Line One	2451 Bert Dr.
Entity Address, City or Town	Hollister
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95023
City Area Code	831
Local Phone Number	637-1100
Entity Common Stock, Shares Outstanding		40,823,387

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 9,290	$ 9,121
Cost of sales	7,081	6,698
Gross profit	2,209	2,423
Operating expenses:
Research and development	860	1,395
Sales and marketing	1,667	2,343
General and administrative	7,381	7,345
Amortization of intangible assets	287	286
Total operating expenses	10,195	11,369
Loss from operations	(7,986)	(8,946)
Other (expenses) income, net
Interest (expense) income, net	(145)	93
Other income, net	0	18
Total other (expenses) income, net	(145)	111
Loss before income taxes	(8,131)	(8,835)
Benefit from income taxes	(34)	(18)
Net loss	$ (8,097)	$ (8,817)
Net loss per share basic and diluted	$ (0.2)	$ (0.31)
Net loss per share basic and diluted	$ (0.2)	$ (0.31)
Weighted average shares used in computing net loss per share -basic	40,804,885	28,181,457
Weighted average shares used in computing net loss per share- diluted	40,804,885	28,181,457

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 21,596	$ 28,484
Accounts receivable, net of allowance for doubtful accounts of $23 thousand and $20 thousand as of March 31, 2024 and December 31, 2023, respectively	4,560	3,948
Inventories, net	11,207	11,594
Prepaid expenses and other current assets	1,460	1,634
Total current assets	38,823	45,660
Property, plant and equipment, net	48,907	50,364
Operating right-of-use lease assets	17,400	16,472
Intangible assets, net	13,952	14,239
Other non-current assets	1,735	1,852
Total assets	120,817	128,587
Current liabilities:
Accounts payable	1,543	1,493
Accrued liabilities	3,574	5,579
Current portion of operating lease liabilities	1,922	1,803
Total current liabilities	7,039	8,875
Deferred tax liabilities	884	919
Other accrued liabilities	78	102
Long-term debt, net	13,178	13,251
Long-term operating lease liabilities	16,260	15,404
Total liabilities	37,439	38,551
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively, zero shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.00001 par value, 490,000,000 shares authorized at March 31, 2024 and December 31, 2023, 40,823,387 and 40,793,848 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	183,261	181,822
Accumulated deficit	(99,883)	(91,786)
Total stockholders’ equity	83,378	90,036
Total liabilities and stockholders' equity	$ 120,817	$ 128,587

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Allowance for doubtful accounts	$ 23	$ 20
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	490,000,000	490,000,000
Common stock, shares issued	40,823,387	40,793,848
Common stock, shares outstanding	40,823,387	40,793,848

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2022	$ 99,885		$ 154,891	$ (55,006)
Beginning Balance (in shares) at Dec. 31, 2022		28,179,423
Issuance of common stock warrants	0
Stock-based compensation	1,010		1,010
Issuance of common stock upon exercise of stock options, shares		10,769
Issuance of common stock upon exercise of stock options	9		9
Net loss	(8,817)			(8,817)
Ending Balance at Mar. 31, 2023	92,087		155,910	(63,823)
Ending Balance (in shares) at Mar. 31, 2023		28,190,192
Beginning Balance at Dec. 31, 2023	$ 90,036		181,822	(91,786)
Beginning Balance (in shares) at Dec. 31, 2023	40,793,848	40,793,848
Issuance of common stock warrants	$ 132		132
Stock-based compensation	1,307		1,307
Vesting of restricted stock units, Shares		29,539
Net loss	(8,097)			(8,097)
Ending Balance at Mar. 31, 2024	$ 83,378		$ 183,261	$ (99,883)
Ending Balance (in shares) at Mar. 31, 2024	40,823,387	40,823,387

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating activities:
Net loss	$ (8,097)	$ (8,817)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	7	2
Inventory reserve	(91)	(144)
Depreciation and amortization	1,636	1,130
Stock-based compensation	1,307	1,010
Deferred taxes	(35)	(19)
Amortization of debt financing costs	84	90
Non-cash lease expense	47	47
Loss on disposal of property, plant, and equipment	49	0
Changes in operating assets and liabilities:
Accounts receivable	(619)	(518)
Inventories	478	240
Prepaid expenses and other current assets	174	271
Other non-current assets	117	102
Accounts payable	133	(386)
Accrued liabilities	(1,724)	(670)
Other	(24)	(22)
Cash used in operating activities	(6,558)	(7,684)
Investing activities:
ProceedsFromSaleOfPropertyPlantAndEquipment	125	0
Purchases of property, plant, and equipment	(112)	(4,312)
Cash used in investing activities	13	(4,312)
Financing activities:
Proceeds from equity financing	(37)	0
Repayment of financed insurance premiums	(306)	0
Payment of at-the-market facility costs	0	(34)
Proceeds from exercise of stock options	0	9
Cash provided by financing activities	(343)	(25)
Change in cash and cash equivalents, and restricted cash	(6,888)	(12,021)
Cash and cash equivalents and restricted cash at beginning of period	28,484	42,236
Cash and cash equivalents and restricted cash at end of period	21,596	30,215
Supplemental cash flow disclosures:
Income taxes paid	0	0
Interest paid, net of amounts capitalized	366	110
Capitalized property, plant, and equipment included in accounts payable and accrued liabilities	5	925
At the market facility costs included in accounts payable and accrued liabilities	0	329
Debt issuance costs included in accrued liabilities	25	30
Issuance of common stock warrants	132	0
Recognition of operating right-of-use lease asset	1,293	(648)
Recognition of operating lease liabilities	$ 1,306	$ (602)

Nature of the Business

Nature of the Business	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	Note 1. Nature of th e Business Teknova produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our product offerings include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions, with catalog and custom, made-to-order products. Teknova manufactures its products at its Hollister, California, headquarters and stocks inventory of raw materials, components, and finished goods at that location. The Company ships products directly from its warehouse in Hollister to its customers and distributors.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Accounting, Presentation and Use of Estimates The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with such rules and regulations. The unaudited condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the results for the interim periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results may differ from those estimates. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the related notes thereto as of and for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2024 (the 2023 Annual Report on Form 10-K). Refer to “ Notes to Financial Statements—Note 2. Summary of Significant Accounting Policies,” within the 2023 Annual Report on Form 10-K for a full list of the Company’s significant accounting policies. The information in those notes has not changed except as a result of normal adjustments in the interim period. Teknova has determined that it operates in one reporting unit, one operating segment, and one reportable segment, as the Chief Operating Decision Maker (CODM) of the Company reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. Going Concern Accounting Standards Codification (ASC) 205-40, Presentation of Financial Statements—Going Concern , requires management to evaluate an entity’s ability to continue as a going concern for the twelve-month period following the date on which the financial statements are available for issuance. Management performed an assessment to determine whether there were conditions or events that, considered individually and in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying unaudited financial statements are being issued. This assessment indicated certain negative conditions and events, described further below, that raise substantial doubt about the Company’s ability to continue as a going concern. As of March 31, 2024, the Company had limited capital resources to fund ongoing operations. During the three months ended March 31, 2024, Teknova incurred net losses of $ 8.1 million. In addition, as of March 31, 2024, the Company had an accumulated deficit of $ 99.9 million and a total principal amount of outstanding borrowings of $ 12.1 million. As of March 31, 2024, the Company had $ 31.8 million of working capital, which included $ 21.6 million in cash and cash equivalents. The Company’s available capital resources may not be sufficient for the Company to continue to meet its obligations as they become due over the next twelve months if the Company cannot improve its operating results or increase its operating cash inflows. If these capital resources are not sufficient, the Company may need to raise additional capital through the sale of equity or debt securities, enter into strategic business collaboration agreements with other companies, seek other funding facilities, or sell assets. However, there can be no assurance that the Company will be able to accomplish any of the foregoing or do so on favorable terms. If the Company is unable to meet its obligations when they become due over the next twelve months through its available capital resources, or obtain new sources of capital when needed, the Company may have to delay expenditures, reduce the scope of its manufacturing operations, reduce or eliminate one or more of its development programs, make significant changes to its operating plan, or cease its operations. As disclosed in Note 10. Long-term Debt, Net, the Company is subject to certain financial covenants as set forth in the Amended Credit Agreement (defined in Note 10). These financial covenants include (i) a trailing twelve months minimum net revenue covenant that must be met each calendar month, and (ii) a requirement to maintain a minimum level of cash at all times through the term of the Amended Credit Agreement. The Company was in compliance with its financial covenants as of March 31, 2024; however, the Company continues to experience unfavorable market conditions, like other companies in the industry. As a result, the Company believes it may be unable to comply with the trailing twelve months revenue covenant for the twelve-month period following the date on which the financial statements are available for issuance. If the Company violates one or more of its covenants under the Amended Credit Agreement, including the monthly revenue covenant, and is not able to obtain a waiver from or agree to an accommodation with the lender with respect to any such violation, the Company could be required to pay all or a portion of the outstanding amount under the Term Loan (defined in Note 10). In that event, the Company may need to seek other sources of capital and there can be no assurances that the Company would be able to do so on acceptable terms. The accompanying unaudited financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and the satisfaction of liabilities in the normal course of business for one year following the issuance of these unaudited financial statements. As such, the accompanying unaudited financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern. Reduction in Workforce On January 11, 2024, the Company carried out a reduction in workforce of approximately 35 positions, aimed at reducing operating expenses. The Company incurred $ 1.3 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2024, in general and administrative expenses. On February 1, 2023, the Company carried out a reduction in workforce of approximately 40 positions, aimed at reducing operating expenses. The Company incurred $ 0.7 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2023, in general and administrative expenses . Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging (ASC 815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Additionally, all disclosure requirements under the guidance are also required for public entities with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of this standard to determine its impact on the Company’s disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which requires disclosure in the rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciliation items in some categories if the items meet a quantitative threshold. The guidance also requires disclosure of income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. The guidance is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of this standard to determine its impact on the Company’s disclosures. Recent Securities and Exchange Commission (SEC) Final Rules Not Yet Adopted In March 2024, the SEC adopted final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which requires registrants to provide certain climate-related information in their registration statements and annual reports. The rules require information about a registrant’s climate-related risks that have materially impacted, or are reasonably likely to have a material impact on its business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in the registrant’s audited financial statements. Disclosure requirements will begin phasing in for fiscal years beginning on or after January 1, 2025. The Company is currently evaluating the impact of these new final rules on its financial statements and disclosures.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3. Revenue Recognition Teknova recognizes revenue from the sale of manufactured products and services when the Company transfers control of promised goods or services to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Control is transferred when the customer has the ability to direct the use of and obtain benefits from the goods or services. The majority of the Company’s sales agreements contain performance obligations satisfied at a point in time when control is transferred to the customer. Teknova’s revenue, disaggregated by product category, was as follows (in thousands): For the Three Months Ended March 31, 2024 2023 Lab Essentials $ 7,266 $ 7,257 Clinical Solutions 1,718 1,609 Other 306 255 Total revenue $ 9,290 $ 9,121 Teknova’s revenue, disaggregated by geographic region, was as follows (in thousands): For the Three Months Ended March 31, 2024 2023 United States $ 8,870 $ 8,726 International 420 395 Total revenue $ 9,290 $ 9,121

Concentrations of Risk

Concentrations of Risk	3 Months Ended
	Mar. 31, 2024
Fair Value, Concentration of Risk, Financial Assets, Balance Sheet Groupings [Abstract]
Concentrations of Risk	Note 4. Concentrations of Risk Customers Customers who accounted for 10% or more of the Company’s revenues and outstanding balance of accounts receivable and contract assets are presented as follows: For the Three Months Ended March 31, As of As of 2024 2023 March 31, 2024 December 31, 2023 Distributor customer A 16 % 19 % 18 % 16 % * Represents less than 10%. The Company’s customers that are distributors, as opposed to direct customers, represent highly diversified customer bases. Suppliers Suppliers who accounted for 10% or more of the Company’s inventory purchases and outstanding balance of accounts payable are presented as follows: For the Three Months Ended March 31, As of As of 2024 2023 March 31, 2024 December 31, 2023 Distributor supplier A 39 % 36 % 20 % 18 % Direct supplier A * 10 % * * * Represents less than 10%. The Company’ s suppliers that are distributors, as opposed to direct suppliers, represent highly diversified supplier bases.

Inventories, Net

Inventories, Net	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventories, Net	Note 5. Inventories, Net Inventories consisted of the following (in thousands): As of As of Finished goods, net $ 7,821 $ 8,573 Work in process 276 47 Raw materials, net 3,110 2,974 Total inventories, net $ 11,207 $ 11,594

Property, Plant and Equipment,

Property, Plant and Equipment, Net	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Note 6. Property, Plant, and Equipment, Net Property, plant, and equipment consisted of the following (in thousands): As of As of Machinery and equipment $ 29,826 $ 30,082 Office furniture and equipment 842 842 Vehicles 291 291 Leasehold improvements 24,726 24,673 55,685 55,888 Less—Accumulated depreciation ( 8,764 ) ( 7,528 ) 46,921 48,360 Construction in progress 1,986 2,004 Total property, plant, and equipment, net $ 48,907 $ 50,364 For the three months ended March 31, 2024 and 2023, depreciation expense was $ 1.3 million and $ 0.8 million, respectively. Teknova capitalizes interest on funds borrowed to finance certain of its capital expenditures. Capitalized interest is recorded as part of an asset’s cost and depreciated over the asset’s useful life. For the three months ended March 31, 2024 and 2023, capitalized interest costs were zero and $ 0.6 million, respectively.

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	Note 7. Leases The Company leases office space, warehouse and manufacturing space, and equipment. The Company ’ s lease agreements have remaining lease terms of one year to 14 years , and some of these leases have renewal and termination options exercisable at the Company’s election. Terms and conditions to extend or terminate such leases are recognized as part of the right-of-use assets and lease liabilities where reasonably certain to be exercised. All of the Company ’ s leases are operating leases. The components of lease expense and other information related to leases were as follows (in thousands): For the Three Months Ended March 31, 2024 2023 Operating lease expense $ 745 $ 761 Variable lease expense 109 55 Total lease expense $ 854 $ 816 Cash paid for amounts included in the measurement of the lease liabilities was $ 0.7 million and $ 0.8 million for the three months ended March 31, 2024 and 2023, respectively. The weighted-average discount rate was 4.9 % and the weighted-average remaining lease term was 8.6 years as of March 31, 2024. Maturities of operating lease liabilities at March 31, 2024 were as follows (in thousands): Amount Remainder of 2024 $ 2,110 2025 2,569 2026 2,627 2027 2,631 2028 2,480 Thereafter 10,297 Total lease payments 22,714 Less: imputed interest ( 4,532 ) Present value of lease liabilities $ 18,182

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Note 8. Intangible Assets, Net The following is a summary of intangible assets with definite and indefinite lives (in thousands): Balance at March 31, 2024 Balance at December 31, 2023 Gross Accumulated Net Gross Accumulated Net Definite Lived: Customer relationships $ 9,180 $ 5,978 $ 3,202 $ 9,180 $ 5,691 $ 3,489 Indefinite Lived: Tradename 10,750 — 10,750 10,750 — 10,750 Total intangible assets $ 19,930 $ 5,978 $ 13,952 $ 19,930 $ 5,691 $ 14,239 For each of the three months ended March 31, 2024 and 2023, amortization expense was $ 0.3 million. As of March 31, 2024, the remaining weighted-average useful life of definite lived intangible assets was 2.8 years. The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands): Amount Remainder of 2024 $ 861 2025 1,148 2026 1,148 2027 45 Estimated future amortization expense of definite-lived intangible assets $ 3,202

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2024
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	Note 9. Accrued Liabilities Accrued liabilities were comprised of the following (in thousands): As of As of Payroll-related $ 1,859 $ 3,826 Deferred revenue 30 16 Insurance premiums and accrued interest 103 409 Loss contingency accrual 300 300 Other 1,282 1,028 Total current accrued liabilities $ 3,574 $ 5,579

Long-Term Debt, Net

Long-Term Debt, Net	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt, Net	Note 10. Long-term Debt, Net On March 8, 2024, the Company entered into limited waivers and amendments (collectively Amendment No. 5) to (i) the May 10, 2022, Amended and Restated Credit and Security Agreement (Term Loan), as amended on November 8, 2022, March 28, 2023, July 13, 2023, and September 19, 2023 and (ii) the May 10, 2022, Amended and Restated Credit and Security Agreement (Revolving Loan) as amended on November 8, 2022, March 28, 2023, July 13, 2023 and September 19, 2023 (together, the Amended Credit Agreement), in each case with the Company as borrower and with MidCap Financial Trust (MidCap) as agent and lender, and the additional lenders from time to time party thereto. Amendment No. 5 modifies the credit facility established under the Amended Credit Agreement, which provided for a $ 57.1 million credit facility (the Credit Facility) consisting of a $ 52.1 million senior secured term loan (the Term Loan) and a $ 5.0 million working capital facility (the Revolver). The interest on the Term Loan is based on the forward-looking one-month term Secured Overnight Financing Rate adjusted upward by 0.10 % (Term SOFR) plus an applicable margin of 7.00 %, subject to a Term SOFR floor of 4.50 %. If any advance under the Term Loan is prepaid at any time, a prepayment fee is based on the amount being prepaid and an applicable percentage amount, such as 4%, 3%, or 1%, based on the date the prepayment is made . Interest on an outstanding balance of the Revolver is payable monthly in arrears at an annual rate of Term SOFR plus an applicable margin of 4.00 %, subject to a Term SOFR floor of 4.50 %. The Amended Credit Agreement includes minimum net revenue requirements that are measured on a trailing twelve-month basis and a minimum cash requirement. Amendment No. 5 reduced the minimum net revenue requirements for future periods up to and including for the twelve months ending December 31, 2024—for example, the Company’s minimum net revenue requirement was reduced for the twelve months ending December 31, 2024, from $ 42.0 million to $ 34.0 million. Amendment No. 5 also removed those requirements for the periods ending January 31, 2025 through December 31, 2025, instead requiring that for each applicable twelve-month period ending after December 31, 2024, the Company’s minimum net revenue requirement will be determined by MidCap in its reasonable discretion in consultation with the Company’s senior management and based on financial statements and projections delivered to MidCap in accordance with the financial reporting requirements in the Amended Credit Agreement, so long as the minimum net revenue requirements for those periods shall not be less than the greater of (x) the applicable minimum net revenue requirement for the twelve-month period ending on the last day of the immediately preceding month and (y) $34.0 million . In addition, Amendment No. 5 also removed the advance rate for finished goods inventory in the determination of the borrowing base for the Revolving Loan and increased the minimum cash requirement from $ 9.0 million to $ 10.0 million. Finally, Amendment No. 5 conditions the next borrowing under the Revolving Loan on the Company achieving net revenue for the preceding twelve-month period of at least $ 38.0 million down from $ 45.0 million. As a condition to the effectiveness of Amendment No. 5, the Company also issued equity-classified warrants with a fair value of $ 0.1 million as described further in Note 11, Stockholder ’s Equity. These warrants were recorded as additional debt issuance costs, which are being amortized to interest expense over the term of the Amended Credit Agreement using the effective interest method . The maturity date of the Credit Facility is May 1, 2027 . On the date of termination of the Term Loan or the date on which the obligations under the Term Loan become due and payable in full, the Company will pay an exit fee in an amount equal to 9.00 % of the total aggregate principal amount of term loans made pursuant to the Term Loan (including amendments thereto) as of such date. All loans issued under the Credit Facility are collateralized by the Company ’s assets. Long-term debt, net consisted of the following (in thousands): As of As of Long-term debt $ 12,135 $ 12,135 Cumulative accretion of exit fee 1,330 1,261 Unamortized debt discount and debt issuance costs ( 287 ) ( 145 ) Long-term debt, net $ 13,178 $ 13,251 At March 31, 2024, the scheduled maturities of the Company's debt obligations were as follows (in thousands): Amount Remainder of 2024 $ — 2025 3,539 2026 6,068 2027 2,528 Total $ 12,135 As of March 31, 2024, the fair value of the Company ’ s debt approximated its carrying value. The fair value of the Company ’ s debt was based on observable market inputs (Level 2).

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 11. Stockholders ’ Equity At-the-Market Facility On March 30, 2023, the Company entered into a sales agreement (the ATM Facility) with Cowen and Company, LLC (Cowen), under which the Company may offer and sell, from time to time, shares of its common stock having aggregate gross proceeds of up to $ 50.0 million. The issuance and sale of these shares pursuant to the ATM Facility are deemed “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the Securities Act), and are registered under the Securities Act. The Company will pay a commission of up to 3.0 % of gross sales proceeds of any common stock sold under the ATM Facility. The aggregate market value of shares eligible for sale under the ATM Facility will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. Warrants to Purchase Common Stock On March 8, 2024, as a condition to the effectiveness of Amendment No. 5, the Company issued to MidCap Funding XXVII a warrant to purchase up to an aggregate of 125,000 shares (the Common Warrant) of common stock with an exercise price of $ 2.9934 per share, subject to adjustment as provided therein. The Common Warrant is exercisable immediately, and will expire on the earlier to occur of the (i) expiration of the Common Warrant pursuant to Section 1.6 thereof, or (ii) tenth (10th) anniversary of the Issue Date (as defined therein). The exercise price and number of shares of common stock issuable upon the exercise of the Common Warrant will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization, or similar transaction, as described in the Common Warrant. MidCap may exercise the Common Warrant for cash or by means of a “cashless exercise.” The Company determined that the Common Warrant is not a liability within the scope of ASC 480, but met the requirements to be classified within stockholders’ equity, because the warrant is indexed to the Company’s own stock and met all of the conditions for equity classification in accordance with ASC 815. Accordingly, the warrants were recorded as a component of additional paid-in capital in the statements of stockholders’ equity at the time of issuance. The Common Warrant was valued using the Black-Scholes option pricing model with the following assumptions: i) fair value of common stock of $ 2.8500 , ii) exercise price of $ 2.9934 , iii) term of 5 years , iv) dividend rate of 0 %, v) volatility of 36.70 %, and vi) risk free interest rate of 4.06 %.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 12. Stock-Based Compensation Equity Incentive Plans The Company maintains a stock incentive plan, that permits the granting of incentive stock options or nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other stock-based awards. The equity-based awards for employees will generally vest over a four-year period, pursuant to two different vesting schedules. For initial equity-based awards granted to employees, the first vest is generally a one-year cliff vest, followed by monthly vesting for the final three years. Thereafter, annual equity-based awards granted to employees typically vest monthly over the four-year vest term. The initial equity-based awards granted to the Company’s non-employee, independent directors upon appointment to the board of directors will vest over a three-year period, with the first vest being a one-year cliff, followed by monthly vesting over the remaining two years. Thereafter, annual equity-based awards granted to the Company’s non-employee, independent directors will cliff vest after one year from the date of grant. Stock Options The following table summarizes the stock option activity for the three months ended March 31, 2024 (in thousands, except share and per share data): Number of Weighted Weighted Average Aggregate Outstanding at January 1, 2024 4,041,807 $ 6.41 7.53 $ 5,159 Granted 727,500 $ 2.85 Exercised — $ — Forfeited ( 391,922 ) $ 10.08 Expired ( 7,186 ) $ 12.07 Outstanding at March 31, 2024 4,370,199 $ 5.48 7.11 $ 3,201 Exercisable at March 31, 2024 2,352,970 $ 5.82 6.03 $ 2,356 Vested and expected to vest at March 31, 2024 4,085,517 $ 5.83 7.27 $ 2,576 The weighted average assumptions used in the Black-Scholes pricing model for stock options granted during the three months ended March 31, 2024, were as follows: For the Three Months Ended March 31, 2024 2023 Estimated dividend yield - % - % Weighted-average expected stock price volatility 35.91 % 35.04 % Weighted-average risk-free interest rate 4.33 % 4.11 % Expected average term of options (in years) 6.25 6.25 Weighted-average fair value of common stock $ 2.85 $ 5.41 Weighted-average fair value per option $ 1.24 $ 2.29 Restricted Stock The following table summarizes the restricted stock unit activity for the three months ended March 31, 2024 (in thousands, except share and per share data): Number of Weighted Weighted Average Aggregate Outstanding at January 1, 2024 155,780 $ 5.05 1.36 $ 581 Granted — $ — Vested ( 29,539 ) $ 5.41 Forfeited ( 21,000 ) $ 5.41 Outstanding at March 31, 2024 105,241 $ 4.88 1.29 $ 279 Vested and expected to vest at March 31, 2024 105,241 $ 4.88 1.29 $ 279 Employee Stock Purchase Plan The Company also maintains an employee stock purchase plan (ESPP) that authorizes the issuance of shares of common stock pursuant to purchase rights granted to eligible employees. Unless otherwise determined by the Company’s board of directors, shares of the Company’s common stock will be purchased for the accounts of employees participating in the Company’s ESPP at a price per share equal to the lesser of (i) 85 % of the fair market value of a share of the Company’s common stock on the first day of an offering; or (ii) 85 % of the fair market value of a share of the Company’s common stock on the date of purchase. Offering periods are generally six months long; offering periods begin on June 1 and December 1 of each year. The Company issued zero shares of common stock under the ESPP during each of the three months ended March 31, 2023 and March 31, 2024. Repricing of Outstanding and Unexercised Options In January 2024, the Company’s board of directors approved a one-time repricing of certain previously granted and still outstanding vested and unvested stock option awards held by eligible employees, executive officers, and non-employee directors . As a result, the exercise price for these awards will be lowered to $ 2.97 per share, which was the closing price of the Company’s common stock as reported on the Nasdaq Global Stock Market on March 14, 2024, so long as the holder remains employed by the Company or continues to serve as a member of the board of directors through September 14, 2025 absent earlier trigger events defined in the option repricing plan. No other terms of the stock options were modified, and the stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the repricing, 1,631,016 vested and unvested stock options outstanding as of March 14, 2024, with original exercise prices ranging from $ 3.02 to $ 27.49 , were repriced. The repricing on March 14, 2024 resulted in incremental stock-based compensation expense of $ 0.9 million, of which $ 0.5 million related to vested stock option awards and was expensed on the repricing date. The remaining $ 0.4 million related to unvested stock option awards and is being amortized on a straight-line basis over the weighted-average vesting period of those awards of approximately 2.38 years as of March 14, 2024. Stock-Based Compensation Expense Stock-based compensation expense included in the accompanying condensed financial statements was as follows (in thousands): For the Three Months Ended March 31, 2024 2023 Cost of sales $ 49 $ 36 Research and development 30 37 Sales and marketing 96 152 General and administrative 1,132 785 Total stock-based compensation expense $ 1,307 $ 1,010 Stock-based compensation expense related to stock options was $ 1.2 million and $ 0.9 million for the three months ended March 31, 2024 and 2023, respectively. Unrecognized compensation expense related to stock options was $ 5.5 million at March 31, 2024, which is expected to be recognized as expense over the weighted-average period of 3.20 years. Stock-based compensation expense related to restricted stock units was $ 0.1 million in each of the three months ended March 31, 2024 and 2023, respectively. Unrecognized compensation expense related to restricted stock units was $ 0.4 million at March 31, 2024, which is expected to be recognized as expense over the weighted-average period of 1.93 years. Stock-based compensation expense related to the ESPP was not significant in either of the three months ended March 31, 2024 and 2023 . Total compensation cost related to the ESPP not yet recognized was not significant at March 31, 2024. As of March 31, 2024, $ 0.1 million has been withheld on behalf of employees for future purchases under the ESPP.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 13. Income Taxes For the three months ended March 31, 2024 the Company's income tax benefit was not significant, compared to the three months ended March 31, 2023, when the Company also recorded a minimal income tax benefit. The effective tax rates for the three months ended March 31, 2024 and 2023 were 0.4 % and 0.2 %, respectively. The effective tax rates differ from the federal statutory rate primarily due to operating losses not expected to produce an income tax benefit. The Company had insignificant unrecognized tax benefits as of March 31, 2024 and 2023. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not expect the balance of unrecognized tax benefits to change significantly over the next twelve months. The Company has not accrued interest or penalties related to uncertain tax positions as of March 31, 2024 and 2023.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Note 14. Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents to the extent they are dilutive. For purposes of this calculation, stock options, restricted stock units, employee stock purchase rights, and warrants to purchase common stock, are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): For the Three Months Ended March 31, 2024 2023 Net loss $ ( 8,097 ) $ ( 8,817 ) Weighted average shares used in computing net loss per share—basic and diluted 40,804,885 28,181,457 Net loss per share—basic and diluted $ ( 0.20 ) $ ( 0.31 ) Th e following is a summary of the common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive: For the Three Months Ended March 31, 2024 2023 Employee share-based awards to purchase common stock 3,914,307 3,833,546 Warrants to purchase common stock 32,967 —

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Parties	Note 15. Related Parties The Company has identified Meeches LLC (Meeches) as a related party through common control. Meeches is controlled by Ted Davis and Irene Davis, founders and current directors, and greater than five percent stockholders of the Company. Prior to May 16, 2023, the Company leased certain real property in Mansfield, Massachusetts, from Meeches. For the three months ended March 31, 2024 and 2023, the Company paid Meeches lease payments of zero and $ 0.1 million, respectively.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 16. Contingencies From time to time, we may become involved in lawsuits and other claims arising from our ordinary course of business. The Company regularly evaluates its exposure to threatened or pending litigation and other business contingencies. Because of the uncertainties related to the amount of loss from litigation and other business contingencies, the recording of losses relating to such exposures requires significant judgment about the potential range of outcomes. We establish loss provisions for matters in which losses are probable and can be reasonably estimated. If a loss is not both probable and reasonably estimable, or if an exposure to loss exists in excess of the amount accrued, the Company assesses whether there is at least a reasonable possibility that a loss, or additional loss, may have been incurred. If there is a reasonable possibility that a loss, or additional loss, may have been incurred, the Company will disclose the estimate of the possible loss or range of loss if it is material and an estimate can be made, or disclose that such an estimate cannot be made. The determination as to whether a loss can reasonably be considered to be possible or probable is based on our assessment, together with legal counsel, regarding the ultimate outcome of the matter. As additional information about current or future litigation or other contingencies becomes available, the Company will assess whether adjustments should be made to legal accruals. In August 2023, a former Teknova employee filed a claim with the California Labor and Workforce Development Agency alleging various causes of action under California’s labor, wage, and hour laws. The plaintiff generally alleges that Teknova did not appropriately calculate and pay meal break premiums and otherwise failed to calculate and pay appropriate overtime wages or bonuses to certain of its California non-exempt employees. A mediation has been scheduled for June 6, 2024. As of March 31, 2024 and December 31, 2023, the Company has accrued its best estimate of potential loss related to a possible settlement of the claims of the former employee and other employees who may assert similar claims, in the amount of $ 0.3 million, which is included within “Accrued liabilities” on the Balance Sheet. The actual loss attributable to the final resolution of this and related claims could differ materially from the Company’s present best estimate.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Accounting, Presentation and Use of Estimates	Basis of Accounting, Presentation and Use of Estimates The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with such rules and regulations. The unaudited condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the results for the interim periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results may differ from those estimates. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the related notes thereto as of and for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2024 (the 2023 Annual Report on Form 10-K). Refer to “ Notes to Financial Statements—Note 2. Summary of Significant Accounting Policies,” within the 2023 Annual Report on Form 10-K for a full list of the Company’s significant accounting policies. The information in those notes has not changed except as a result of normal adjustments in the interim period. Teknova has determined that it operates in one reporting unit, one operating segment, and one reportable segment, as the Chief Operating Decision Maker (CODM) of the Company reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.
Going Concern	Going Concern Accounting Standards Codification (ASC) 205-40, Presentation of Financial Statements—Going Concern , requires management to evaluate an entity’s ability to continue as a going concern for the twelve-month period following the date on which the financial statements are available for issuance. Management performed an assessment to determine whether there were conditions or events that, considered individually and in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying unaudited financial statements are being issued. This assessment indicated certain negative conditions and events, described further below, that raise substantial doubt about the Company’s ability to continue as a going concern. As of March 31, 2024, the Company had limited capital resources to fund ongoing operations. During the three months ended March 31, 2024, Teknova incurred net losses of $ 8.1 million. In addition, as of March 31, 2024, the Company had an accumulated deficit of $ 99.9 million and a total principal amount of outstanding borrowings of $ 12.1 million. As of March 31, 2024, the Company had $ 31.8 million of working capital, which included $ 21.6 million in cash and cash equivalents. The Company’s available capital resources may not be sufficient for the Company to continue to meet its obligations as they become due over the next twelve months if the Company cannot improve its operating results or increase its operating cash inflows. If these capital resources are not sufficient, the Company may need to raise additional capital through the sale of equity or debt securities, enter into strategic business collaboration agreements with other companies, seek other funding facilities, or sell assets. However, there can be no assurance that the Company will be able to accomplish any of the foregoing or do so on favorable terms. If the Company is unable to meet its obligations when they become due over the next twelve months through its available capital resources, or obtain new sources of capital when needed, the Company may have to delay expenditures, reduce the scope of its manufacturing operations, reduce or eliminate one or more of its development programs, make significant changes to its operating plan, or cease its operations. As disclosed in Note 10. Long-term Debt, Net, the Company is subject to certain financial covenants as set forth in the Amended Credit Agreement (defined in Note 10). These financial covenants include (i) a trailing twelve months minimum net revenue covenant that must be met each calendar month, and (ii) a requirement to maintain a minimum level of cash at all times through the term of the Amended Credit Agreement. The Company was in compliance with its financial covenants as of March 31, 2024; however, the Company continues to experience unfavorable market conditions, like other companies in the industry. As a result, the Company believes it may be unable to comply with the trailing twelve months revenue covenant for the twelve-month period following the date on which the financial statements are available for issuance. If the Company violates one or more of its covenants under the Amended Credit Agreement, including the monthly revenue covenant, and is not able to obtain a waiver from or agree to an accommodation with the lender with respect to any such violation, the Company could be required to pay all or a portion of the outstanding amount under the Term Loan (defined in Note 10). In that event, the Company may need to seek other sources of capital and there can be no assurances that the Company would be able to do so on acceptable terms. The accompanying unaudited financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and the satisfaction of liabilities in the normal course of business for one year following the issuance of these unaudited financial statements. As such, the accompanying unaudited financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.
Reduction in Workforce	Reduction in Workforce On January 11, 2024, the Company carried out a reduction in workforce of approximately 35 positions, aimed at reducing operating expenses. The Company incurred $ 1.3 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2024, in general and administrative expenses. On February 1, 2023, the Company carried out a reduction in workforce of approximately 40 positions, aimed at reducing operating expenses. The Company incurred $ 0.7 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2023, in general and administrative expenses
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging (ASC 815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Additionally, all disclosure requirements under the guidance are also required for public entities with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of this standard to determine its impact on the Company’s disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which requires disclosure in the rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciliation items in some categories if the items meet a quantitative threshold. The guidance also requires disclosure of income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. The guidance is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of this standard to determine its impact on the Company’s disclosures.
Recent Securities and Exchange Commission (SEC) Final Rules Not Yet Adopted [Policy Text Block]	Recent Securities and Exchange Commission (SEC) Final Rules Not Yet Adopted In March 2024, the SEC adopted final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which requires registrants to provide certain climate-related information in their registration statements and annual reports. The rules require information about a registrant’s climate-related risks that have materially impacted, or are reasonably likely to have a material impact on its business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in the registrant’s audited financial statements. Disclosure requirements will begin phasing in for fiscal years beginning on or after January 1, 2025. The Company is currently evaluating the impact of these new final rules on its financial statements and disclosures.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Teknova’s revenue, disaggregated by product category, was as follows (in thousands): For the Three Months Ended March 31, 2024 2023 Lab Essentials $ 7,266 $ 7,257 Clinical Solutions 1,718 1,609 Other 306 255 Total revenue $ 9,290 $ 9,121 Teknova’s revenue, disaggregated by geographic region, was as follows (in thousands): For the Three Months Ended March 31, 2024 2023 United States $ 8,870 $ 8,726 International 420 395 Total revenue $ 9,290 $ 9,121

Concentrations of Risk (Tables)

Concentrations of Risk (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value, Concentration of Risk, Financial Assets, Balance Sheet Groupings [Abstract]
Summary Of Company Revenues And Outstanding Balance Of Accounts Receivable	Customers who accounted for 10% or more of the Company’s revenues and outstanding balance of accounts receivable and contract assets are presented as follows: For the Three Months Ended March 31, As of As of 2024 2023 March 31, 2024 December 31, 2023 Distributor customer A 16 % 19 % 18 % 16 % * Represents less than 10%.
Summary Of Company Inventory Purchases And Outstanding Balance Of Accounts Payable	Suppliers who accounted for 10% or more of the Company’s inventory purchases and outstanding balance of accounts payable are presented as follows: For the Three Months Ended March 31, As of As of 2024 2023 March 31, 2024 December 31, 2023 Distributor supplier A 39 % 36 % 20 % 18 % Direct supplier A * 10 % * * * Represents less than 10%.

Inventories, Net (Tables)

Inventories, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory, Net	Inventories consisted of the following (in thousands): As of As of Finished goods, net $ 7,821 $ 8,573 Work in process 276 47 Raw materials, net 3,110 2,974 Total inventories, net $ 11,207 $ 11,594

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Summary of Components of Property, Plant and Equipment, Net	Property, plant, and equipment consisted of the following (in thousands): As of As of Machinery and equipment $ 29,826 $ 30,082 Office furniture and equipment 842 842 Vehicles 291 291 Leasehold improvements 24,726 24,673 55,685 55,888 Less—Accumulated depreciation ( 8,764 ) ( 7,528 ) 46,921 48,360 Construction in progress 1,986 2,004 Total property, plant, and equipment, net $ 48,907 $ 50,364

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule Of Maturities Of Operating Lease Liabilities	Maturities of operating lease liabilities at March 31, 2024 were as follows (in thousands): Amount Remainder of 2024 $ 2,110 2025 2,569 2026 2,627 2027 2,631 2028 2,480 Thereafter 10,297 Total lease payments 22,714 Less: imputed interest ( 4,532 ) Present value of lease liabilities $ 18,182

Lease Costs And Other Informati

Lease Costs And Other Information Related (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Component of Lease Cost	The components of lease expense and other information related to leases were as follows (in thousands): For the Three Months Ended March 31, 2024 2023 Operating lease expense $ 745 $ 761 Variable lease expense 109 55 Total lease expense $ 854 $ 816

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets with Definite and Indefinite Lives	The following is a summary of intangible assets with definite and indefinite lives (in thousands): Balance at March 31, 2024 Balance at December 31, 2023 Gross Accumulated Net Gross Accumulated Net Definite Lived: Customer relationships $ 9,180 $ 5,978 $ 3,202 $ 9,180 $ 5,691 $ 3,489 Indefinite Lived: Tradename 10,750 — 10,750 10,750 — 10,750 Total intangible assets $ 19,930 $ 5,978 $ 13,952 $ 19,930 $ 5,691 $ 14,239
Schedule of Future Amortization Expense	The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands): Amount Remainder of 2024 $ 861 2025 1,148 2026 1,148 2027 45 Estimated future amortization expense of definite-lived intangible assets $ 3,202

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Accrued Liabilities, Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities were comprised of the following (in thousands): As of As of Payroll-related $ 1,859 $ 3,826 Deferred revenue 30 16 Insurance premiums and accrued interest 103 409 Loss contingency accrual 300 300 Other 1,282 1,028 Total current accrued liabilities $ 3,574 $ 5,579

Long-Term Debt, Net (Tables)

Long-Term Debt, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Summary of Components of Carrying Value of Long-Term Debt	Long-term debt, net consisted of the following (in thousands): As of As of Long-term debt $ 12,135 $ 12,135 Cumulative accretion of exit fee 1,330 1,261 Unamortized debt discount and debt issuance costs ( 287 ) ( 145 ) Long-term debt, net $ 13,178 $ 13,251
Schedule of Maturities of Term Loan	At March 31, 2024, the scheduled maturities of the Company's debt obligations were as follows (in thousands): Amount Remainder of 2024 $ — 2025 3,539 2026 6,068 2027 2,528 Total $ 12,135

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Stock Options Activity	The following table summarizes the stock option activity for the three months ended March 31, 2024 (in thousands, except share and per share data): Number of Weighted Weighted Average Aggregate Outstanding at January 1, 2024 4,041,807 $ 6.41 7.53 $ 5,159 Granted 727,500 $ 2.85 Exercised — $ — Forfeited ( 391,922 ) $ 10.08 Expired ( 7,186 ) $ 12.07 Outstanding at March 31, 2024 4,370,199 $ 5.48 7.11 $ 3,201 Exercisable at March 31, 2024 2,352,970 $ 5.82 6.03 $ 2,356 Vested and expected to vest at March 31, 2024 4,085,517 $ 5.83 7.27 $ 2,576
Schedule of Weighted-Average Assumptions used in Black-Scholes Option-Pricing Model	The weighted average assumptions used in the Black-Scholes pricing model for stock options granted during the three months ended March 31, 2024, were as follows: For the Three Months Ended March 31, 2024 2023 Estimated dividend yield - % - % Weighted-average expected stock price volatility 35.91 % 35.04 % Weighted-average risk-free interest rate 4.33 % 4.11 % Expected average term of options (in years) 6.25 6.25 Weighted-average fair value of common stock $ 2.85 $ 5.41 Weighted-average fair value per option $ 1.24 $ 2.29
Schedule of Restricted Stock Unit Activity	The following table summarizes the restricted stock unit activity for the three months ended March 31, 2024 (in thousands, except share and per share data): Number of Weighted Weighted Average Aggregate Outstanding at January 1, 2024 155,780 $ 5.05 1.36 $ 581 Granted — $ — Vested ( 29,539 ) $ 5.41 Forfeited ( 21,000 ) $ 5.41 Outstanding at March 31, 2024 105,241 $ 4.88 1.29 $ 279 Vested and expected to vest at March 31, 2024 105,241 $ 4.88 1.29 $ 279
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense included in the accompanying condensed financial statements was as follows (in thousands): For the Three Months Ended March 31, 2024 2023 Cost of sales $ 49 $ 36 Research and development 30 37 Sales and marketing 96 152 General and administrative 1,132 785 Total stock-based compensation expense $ 1,307 $ 1,010

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Computation of Basic And Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): For the Three Months Ended March 31, 2024 2023 Net loss $ ( 8,097 ) $ ( 8,817 ) Weighted average shares used in computing net loss per share—basic and diluted 40,804,885 28,181,457 Net loss per share—basic and diluted $ ( 0.20 ) $ ( 0.31 )
Summary of Common Stock Equivalents Excluded from Calculation of Diluted Loss per Share	Th e following is a summary of the common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive: For the Three Months Ended March 31, 2024 2023 Employee share-based awards to purchase common stock 3,914,307 3,833,546 Warrants to purchase common stock 32,967 —

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Additional Information) (Details) $ in Thousands			3 Months Ended
	Jan. 11, 2024 USD ($) Positions	Feb. 01, 2023 USD ($) Positions	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Segment Reporting, Asset Reconciling Item [Line Items]
Net loss			$ (8,097)	$ (8,817)
Accumulated deficit			(99,883)		$ (91,786)
Long-term debt			12,135		12,135
Working capital			31,800
Cash and cash equivalents			$ 21,596		$ 28,484
Reduction in Force [Member ]
Segment Reporting, Asset Reconciling Item [Line Items]
Reduction in Workforce Of Positions | Positions	35	40
Severance And Other Related Termination Benefits	$ 1,300	$ 700

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation Of Revenue [Line Items]
Revenue	$ 9,290	$ 9,121
United States [Member]
Disaggregation Of Revenue [Line Items]
Revenue	8,870	8,726
International [Member]
Disaggregation Of Revenue [Line Items]
Revenue	420	395
Lab Essentials [Member]
Disaggregation Of Revenue [Line Items]
Revenue	7,266	7,257
Clinical Solutions [Member]
Disaggregation Of Revenue [Line Items]
Revenue	1,718	1,609
Other [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 306	$ 255

Concentrations of Risk - Summar

Concentrations of Risk - Summary of revenues and outstanding balance of accounts receivable (Details) - Distributor supplier A - Customers Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Accounts Receivable [Member]
Product Information [Line Items]
Concentration Risk Percentage	18%		16%
Revenue Benchmark [Member]
Product Information [Line Items]
Concentration Risk Percentage1	16%	19%

Concentrations of Risk - Summ_2

Concentrations of Risk - Summary of inventory purchases and outstanding balance of accounts payable (Details) - Customers Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Distributor supplier A | Total Accounts Payable [Member]
Product Information [Line Items]
Concentration Risk Percentage	20%		18%
Distributor supplier A | Inventory Purchases [Member]
Product Information [Line Items]
Concentration Risk Percentage1	39%	36%
Direct supplier A | Inventory Purchases [Member]
Product Information [Line Items]
Concentration Risk Percentage1		10%

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Finished goods, net	$ 7,821	$ 8,573
Work in process	276	47
Raw materials, net	3,110	2,974
Total inventories, net	$ 11,207	$ 11,594

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Summary of Components of Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 55,685	$ 55,888
Less—Accumulated depreciation	(8,764)	(7,528)
Property, plant and equipment, after depreciation	46,921	48,360
Construction in progress	1,986	2,004
Total property, plant and equipment, net	48,907	50,364
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	29,826	30,082
Office Furniture and Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	842	842
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	291	291
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 24,726	$ 24,673

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 1.3	$ 0.8
Capitalized interest costs	$ 0	$ 0.6

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Lease liabilities cash paid	$ 0.7	$ 0.8
Weighted-average discount rate	4.90%
Weighted-average remaining lease term	8 years 7 months 6 days
Maximum [Member]
Remaining lease terms	14 years
Minimum [Member]
Remaining lease terms	1 year

Leases - Schedule - Lease Costs

Leases - Schedule - Lease Costs And Other Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Lessee Disclosure [Abstract]
Operating lease expense	$ 745	$ 761
Variable lease expense	109	55
Total lease expense	$ 854	$ 816

Leases - Schedule of maturities

Leases - Schedule of maturities of operating lease liabilities (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Lessee Disclosure [Abstract]
Remainder of 2024	$ 2,110
2025	2,569
2026	2,627
2027	2,631
2028	2,480
Thereafter	10,297
Total lease payments	22,714
Less: imputed interest	(4,532)
Present value of lease liabilities	$ 18,182

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Intangible Assets [Line Items]
Amortization of intangible assets	$ 287	$ 286
Acquired finite-lived intangible assets, weighted average useful life	2 years 9 months 18 days

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Intangible Assets with Definite and Indefinite Lives (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	$ 5,978	$ 5,691
Intangible Assets, Gross	19,930	19,930
Intangible assets, net	13,952	14,239
Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets, Gross	10,750	10,750
Indefinite-Lived Intangible Assets, Accumulated Amortization	0	0
Intangible assets, net	10,750	10,750
Customer Relationships [Member]
Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	9,180	9,180
Finite-Lived Intangible Assets, Accumulated Amortization	5,978	5,691
Intangible assets, net	$ 3,202	$ 3,489

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Future Amortization Expense (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2024	$ 861
2025	1,148
2026	1,148
2027	45
Estimated future amortization expense of definite-lived intangible assets	$ 3,202

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Payroll-related	$ 1,859	$ 3,826
Deferred revenue	30	16
Insurance premiums and accrued interest	103	409
Loss contingency accrual	300	300
Other	1,282	1,028
Total current accrued liabilities	$ 3,574	$ 5,579

Long-Term Debt, Net - Additiona

Long-Term Debt, Net - Additional information (Details) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
	Mar. 08, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Line of credit working capital	$ 5,000
Line of Credit Facility, Description	If any advance under the Term Loan is prepaid at any time, a prepayment fee is based on the amount being prepaid and an applicable percentage amount, such as 4%, 3%, or 1%, based on the date the prepayment is made
Debt Covenant Description	No. 5 also removed those requirements for the periods ending January 31, 2025 through December 31, 2025, instead requiring that for each applicable twelve-month period ending after December 31, 2024, the Company’s minimum net revenue requirement will be determined by MidCap in its reasonable discretion in consultation with the Company’s senior management and based on financial statements and projections delivered to MidCap in accordance with the financial reporting requirements in the Amended Credit Agreement, so long as the minimum net revenue requirements for those periods shall not be less than the greater of (x) the applicable minimum net revenue requirement for the twelve-month period ending on the last day of the immediately preceding month and (y) $34.0 million
Fair value of equity-classified warrants issued	$ 100	$ 132	$ 0
Term loan exit fee percent	9%
Long-term Debt, Gross		12,135			$ 12,135
Long-term debt, net		$ 13,178			$ 13,251
Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Revenue	$ 45,000
Maturity date	May 01, 2027
Amended Credit Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Revenue	$ 38,000
Amended Credit Agreement [Member] | Forecast [Member] | Maximum [Member]
Debt Instrument [Line Items]
Revenue				$ 34,000
Amended Credit Agreement [Member] | Forecast [Member] | Minimum [Member]
Debt Instrument [Line Items]
Revenue				$ 42,000
Amended Credit Agreement [Member] | SOFR Floor [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	4.50%
Amended Credit Agreement [Member] | SOFR [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	4%
Adjusted upward rate	0.10%
Term SOFR floor	4.50%
The Facility [Member]
Debt Instrument [Line Items]
Maximum amount borrowed	$ 57,100
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Maximum amount borrowed	$ 52,100
Term Loan [Member] | Amended Credit Agreement [Member] | SOFR [Member]
Debt Instrument [Line Items]
Applicable margin	7%
Amended Revolving Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Minimum cash requirement	$ 10,000
Amended Revolving Loan [Member] | Minimum [Member]
Debt Instrument [Line Items]
Minimum cash requirement	$ 9,000

Long-Term Debt, Net - Summary o

Long-Term Debt, Net - Summary of Components of Carrying Value of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Long-term debt	$ 12,135	$ 12,135
Cumulative accretion of exit fee	1,330	1,261
Unamortized debt discount and debt issuance costs	(287)	(145)
Long-term debt, net	$ 13,178	$ 13,251

Long-Term Debt, Net - Summary_2

Long-Term Debt, Net - Summary of Scheduled Maturities of Term Loan (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Long-Term Debt, Unclassified [Abstract]
Remainder of 2024	$ 0
2025	3,539
2026	6,068
2027	2,528
Total	$ 12,135

Stockholders' Equity (Additiona

Stockholders' Equity (Additional Information) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions			3 Months Ended
	Mar. 08, 2024	Mar. 30, 2023	Mar. 31, 2024	Mar. 31, 2023
Stockholders' Equity Note [Line Items]
Expected term			6 years 3 months	6 years 3 months
Expected dividend yield			0%	0%
Risk free interest rate			4.33%	4.11%
At-the-Market Facility [Member]
Stockholders' Equity Note [Line Items]
Common stock aggregate gross proceeds		$ 50
Gross sales proceeds		3%
Warrant [Member]
Stockholders' Equity Note [Line Items]
Warrants to purchase common stock	125,000
Exercise price	$ 2.9934
Fair value of common stock, per share	$ 2.85
Expected term	5 years
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Stockholders' Equity Note [Line Items]
Expected dividend yield	0%
Warrant [Member] | Measurement Input, Price Volatility [Member]
Stockholders' Equity Note [Line Items]
Expected volatility rate	36.70%
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Stockholders' Equity Note [Line Items]
Risk free interest rate	4.06%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Mar. 14, 2024	Mar. 31, 2024	Mar. 31, 2023
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 1.2	$ 0.9
Unrecognized stock-based compensation expense		$ 5.5
Weighted-average recognition period		3 years 2 months 12 days
Number of shares vested and unvested stock options outstanding		4,085,517
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 0.1	$ 0.1
Unrecognized stock-based compensation expense		$ 0.4
Weighted-average recognition period		1 year 11 months 4 days
2021 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Discount from market price, offering date		85%
Discount from market price, purchase date		85%
Common stock, new shares issued		0
Amount withheld for employees		$ 0.1
Repricing of Outstanding and Unexercised Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Incremental stock-based compensation expense	$ 0.9
New excercise price	$ 2.97
Number of shares vested and unvested stock options outstanding	1,631,016
Exercise prices original low	$ 3.02
Exercise prices original high	$ 27.49
Vested stock option awards expensed repricing	$ 0.5
Unvested stock option awards unrecognized expense repricing	$ 0.4
Weighted average vesting period terms repricing	2 years 4 months 17 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Options Activity (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding, Beginning balance	4,041,807
Number of Options, Granted	727,500
Number of Options, Exercised	0
Number of Options, Forfeited	(391,922)
Number of Options expired	(7,186)
Number of Options Outstanding, Ending Balance	4,370,199	4,041,807
Number of Options, Exercisable, Ending balance	2,352,970
Number of shares vested and unvested stock options outstanding	4,085,517
Weighted Average Exercise Price per Share, Options outstanding, Beginning balance	$ 6.41
Weighted Average Exercise Price per Share, Granted	2.85
Weighted Average Exercise Price per Share, Exercised	0
Weighted Average Exercise Price per Share, forfeited	10.08
Weighted Average Exercise Price Per Share, Expired	12.07
Weighted Average Exercise Price per Share, Options outstanding, Ending balance	5.48	$ 6.41
Weighted Average Exercise Price per Share, Exercisable, Ending balance	5.82
Weighted Average Exercise Price per share, Vested and expected to vest, Ending balance	$ 5.83
Weighted Average Exercise Price per Share, Exercisable	7 years 3 months 7 days
Weighted Average Remaining Contractual Term (in years), Options outstanding	7 years 1 month 9 days	7 years 6 months 10 days
Weighted Average Remaining Contractual Term (in years), Exercisable	6 years 10 days
Aggregate Intrinsic Value, Options outstanding	$ 3,201	$ 5,159
Aggregate Intrinsic Value, Exercisable	2,356
Aggregate Intrinsic Value, Vested and expected to vest	$ 2,576

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Weighted-Average Assumptions used in Black-Scholes Option-Pricing Model (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Estimated dividend yield	0%	0%
Weighted-average expected stock price volatility	35.91%	35.04%
Weighted-average risk-free interest rate	4.33%	4.11%
Expected average term of options (in years)	6 years 3 months	6 years 3 months
Weighted-average fair value of common stock	$ 2.85	$ 5.41
Weighted-average fair value per option	$ 1.24	$ 2.29

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding at January 1, 2024, Beginning balance	155,780
RSU, Granted	0
RSU, Vested	(29,539)
RSU, Forfeited	(21,000)
Outstanding at March 31, 2024 Ending balance	105,241	155,780
Number of Shares, Vested and expected to vest at March 31, 2024	105,241
Weighted Average Grant Fair Value, Beginning Balance	$ 5.05
Weighted Average Grant Date Fair Valu per Share, Vested and expected to vest	4.88
Weighted Average Grant Fair Value, Granted	0
Weighted Average Grant Fair Value, Vested	5.41
Weighted Average Grant Fair Value, Forfeited	5.41
Weighted Average Grant Fair Value, Ending Balance	$ 4.88	$ 5.05
Weighted Average Remaining Contractual Term (in years), Options outstanding	1 year 3 months 14 days	1 year 4 months 9 days
Weighted Average Remaining Contractual Term, Vested and expected to vest at March 31, 2024	1 year 3 months 14 days
Aggregate Intrinsic Value, Outstanding	$ 279	$ 581
Aggregate Intrinsic Value, Vested and expected to vest at March 31, 2024	$ 279

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,307	$ 1,010
Cost of Sales [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	49	36
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	30	37
Selling and Marketing Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	96	152
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,132	$ 785

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Effective Tax Rate	0.40%	0.20%

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net (Loss) Income Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net loss	$ (8,097)	$ (8,817)
Weighted average shares used in computing net loss per share -basic	40,804,885	28,181,457
Weighted average shares used in computing net loss per share- diluted	40,804,885	28,181,457
Net loss per share basic and diluted	$ (0.2)	$ (0.31)
Net loss per share basic and diluted	$ (0.2)	$ (0.31)

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Common Stock Equivalents Excluded from Calculation of Diluted Loss per Share Attributable to Common Stockholders (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Employee Share-based Awards to Purchase Common Stock [Member]
Employee share-based awards to purchase common stock	3,914,307	3,833,546
Warrants to Purchase Common Stock [Member]
Employee share-based awards to purchase common stock	32,967	0

Related Parties - Additional In

Related Parties - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Meeches L L C [Member]
Related Party Transaction [Line Items]
Payment for Rent Expense	$ 0	$ 0.1

Contingencies - Additional Info

Contingencies - Additional Information (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Loss contingency, accrual	$ 0.3	$ 0.3